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Background: Patients with non-ischemic dilated cardiomyopathy NIDC are at risk of arrhythmias and sudden cardiac death (SCD). The likely 
arrhythmia substrate is myocardial fibrosis. We tested the hypothesis that the presence and extent of fibrosis characterized by late gadolinium 
enhancement (LGE) cardiac magnetic resonance (CMR) may help risk stratify patients with NIDC referred for an implantable cardioverter defibrillator 
(ICD) therapy for primary prevention of SCD.
Methods: One hundred and nine patients ((61% male, mean age of 50±14 years, mean left ventricular ejection fraction of 25±9%) with a class 1 
indication for ICD insertion for primary prevention of SCD at two institutions underwent an LGE-CMR study and were prospectively followed. Events of 
interest were defined as a combination of death and appropriate ICD therapy.
Results: Myocardial fibrosis by LGE-CMR was identified in 59 patients (54%). During the median follow-up period of 34 months there were 30 
events (10 deaths and 20 appropriate ICD therapies). Univariate analysis showed that the presence and the extent of LGE demonstrated the 
strongest unadjusted association with cardiac events (LGE, hazard ratio (HR): 5.8, chi-squared 12.7, P<0.001; LGE extent, HR 1.16 per 1% increase 
in LGE extent, chi-squared 40.1, P<0.001). In multivariable analysis, the presence of LGE predicted cardiac events independent of age, gender, 
functional class, and ejection fraction. Patients with LGE had a combined event rate of 15% per year, a mortality rate of 5.5% per year, and an ICD 
therapy rate of 9.5% per year in comparison to LGE negative patients who had a combined event rate of 2.6% per year, a mortality rate of 0.7% per 
year and an ICD therapy rate of 1.9% per year. When the extent of LGE was quantified, patients with an LGE extent of >5.6% had an overall event rate 
of 23% per year.
Conclusions: LGE is a powerful marker of risk in patients with NIDC who meet criteria for ICD insertion.
